- Manufacturing Excellence. Delivering Trust
UNITED PHARMA INTERNATIONAL P.L.C (UPI)
Shaping the Future of Pharmaceutical Manufacturing
- Explore Our Vision
- No Commitment Required
We are proud to collaborate with a network of trusted organizations to achieve our vision.
- Pioneering Pharmaceuticals, For a Healthier Tomorrow
Shaping the Future of Pharmaceutical Manufacturing
United Pharma International (P.L.C) is a public limited company committed to excellence, producing essential medicines in our state-of-the-art, FDA-standard facility.
Advanced Manufacturing & Quality Control
Our facility operates under strict FDA cGMP standards, from raw material sourcing to sterile packaging, ensuring excellence in every unit.
High-Quality Pharmaceuticals, Ready for Market
Producing 60 million vials of injectable Cephalosporins annually to meet the critical needs of national and international healthcare markets.
Establishing Centers of Excellence
We are actively planning the foundation of key institutions that will drive medical innovation and set new standards in the region.
Building a Comprehensive Medical Sector
Our vision extends beyond manufacturing to create an integrated healthcare ecosystem built on strategic pillars of growth and innovation.
- Key Features
Our Core Pillars of Excellence and Growth
Discover the core principles and strategic initiatives that define our commitment to shaping the future of health.
Advanced Manufacturing
Operating a state-of-the-art facility built to FDA cGMP standards with a capacity of 60 million vials annually.
Strategic Investment
Join our vision through our public offering of 25% of company shares, designed for strategic growth and high-impact returns.
Regional & Global Expansion
Actively pursuing acquisitions in Sudan and the Middle East , with plans for establishing a new facility in KSA.
Future of R&D
Committed to establishing advanced R&D centers supported by clinical studies to drive pharmaceutical innovation.
Uncompromising Quality
Adherence to the highest global standards, with a future vision for WHO-Certified Quality Control Labs.
Investor Benefits
Swift approvals ensuring your business stays ahead in crucial decisions.
- INVESTMENT OPPORTUNITY
A Strategic Investment in the Future of Health
Join a public limited company with state-of-the-art facilities , a clear vision for expansion , and a commitment to high-impact returns.
- UPCOMING EVENTS
Witness Our Progress Firsthand
We invite all founders and stakeholders to our upcoming General Assembly meeting in Port Sudan. Join us to discuss the future of the company and witness our commitment to transparent governance firsthand.
Financial Performance & Projections
Review of the company’s financial standing and discussion of the strategic outlook, including projected returns for investors.
Expansion Strategy Ratification
Presentation and approval of the company’s expansion plans, including acquisitions in Sudan, the Middle East, and establishing a new site in KSA.
Future Vision & R&D Roadmap
Outlining the long-term vision for an integrated medical sector, including the roadmap for establishing R&D centers and a specialized university.
Shareholder Benefits & Governance
Discussion and voting on unique shareholder benefits, such as the solidarity fund, and reinforcing our commitment to transparent corporate governance.
- faqs
Frequently Asked Questions
Find quick answers to common questions about our investment opportunities, our state-of-the-art facilities, and our vision for the future of healthcare.
UPI is a public limited company (P.L.C) specializing in pharmaceutical manufacturing. We are an extension of our founding entity, Ibaa Pharmaceutical Company , and are focused on producing high-quality injectable medicines in our state-of-the-art facility.
You can invest through our public offering (IPO), where 25% of the company’s shares will be floated. The anticipated price is approximately QAR 3 / AED 3 / SAR 3 / SDG 4,000 per share. The initial offer for founders at a special price concluded on September 25th, 2025.
Our primary facility is a state-of-the-art factory for injectable Cephalosporins, built to FDA cGMP standards. It has a production capacity of 60 million vials per year , with 50% dedicated to the national market.
Our future vision is to build a complete, high-quality medical sector. This includes establishing a specialized university , advanced R&D centers , WHO-certified QC labs , and a bioequivalence center.
The General Assembly is scheduled to convene, God willing, on October 10, 2025, at the Coral Hotel in the City of Port Sudan.